摘要：This short note discusses the politics of TRIPS compliance and legal intricacies involved in India’s attempt to read further limitations into TRIPS. It further explains how hard the Committee (entrusted with the task of reading further limitations into TRIPS) will find its tight rope walk. Will the Committee’s Report open the pandora’s box yet again? – the box this time contains all sorts of controversies on pharmaceutical patents
